NeuroPace CEO uses share withholding for taxes
NeuroPace CEO Joel Becker reported a tax-related share withholding tied to a restricted stock unit vesting.
Rhea-AI Filing Summary
NeuroPace CEO Joel Becker reported a tax-related share withholding tied to a restricted stock unit vesting. On February 27, 2026, 1,126 shares of common stock were withheld by the company at $14.58 per share to cover tax obligations. After this tax-withholding disposition, Becker directly owned 101,960 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise Price or Tax Liability: 1,126 shares
Exercise Price or Tax Liability
1 txn
Insider
Becker Joel
Role
CHIEF EXECUTIVE OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 1,126 | $14.58 | $16K |
Holdings After Transaction:
Common Stock — 101,960 shares (Direct)
Footnotes (1)
- F1. Represents the number of shares withheld by the Issuer on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award.
FAQ
What insider transaction did NeuroPace (NPCE) CEO Joel Becker report?
Joel Becker reported a tax-withholding disposition of 1,126 NeuroPace common shares. The shares were withheld by the company on February 27, 2026 to satisfy tax obligations from a restricted stock unit vesting, rather than sold in an open-market transaction.
Was the NeuroPace (NPCE) CEO’s Form 4 transaction an open-market sale?
The transaction was not an open-market sale. It was a tax-withholding disposition, where 1,126 shares were withheld by NeuroPace to cover tax obligations arising from a restricted stock unit vesting on February 27, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.